deltatrials
Recruiting PHASE2 NCT01639508

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Sponsor: Exelixis

Conditions Non-Small Cell Lung Cancer
Interventions Cabozantinib
Updated 23 times since 2017 Last updated: Dec 12, 2025 Started: Jul 31, 2012 Primary completion: Jul 31, 2026 Completion: Jul 31, 2026

Listed as NCT01639508, this PHASE2 trial focuses on Non-Small Cell Lung Cancer and remains actively recruiting participants. Sponsored by Exelixis, it has been updated 23 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

23 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting PHASE2

  2. Jul 2025 — Jan 2026 [monthly]

    Recruiting PHASE2

  3. Sep 2024 — Jul 2025 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Jul 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 18 earlier versions

  1. Jul 2022 — Jul 2023 [monthly]

    Recruiting PHASE2

  2. Nov 2021 — Jul 2022 [monthly]

    Recruiting PHASE2

  3. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  5. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Jul 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  7. Mar 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  8. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  9. May 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  10. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2

  11. Dec 2018 — Apr 2019 [monthly]

    Recruiting PHASE2

  12. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  13. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  14. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  15. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  16. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  17. Feb 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

  18. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Exelixis
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Basking Ridge, United States
  • • Commack, United States
  • • Harrison, United States
  • • Middletown, United States
  • • Montvale, United States
  • • New York, United States
  • • Uniondale, United States